Literature DB >> 20527019

The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.

Donatella Aldinucci1, Annunziata Gloghini, Antonio Pinto, Rosaria De Filippi, Antonino Carbone.   

Abstract

It has become clear that cancer is not merely a growth of autonomously proliferating cells, but that other non-malignant cell types are a functional part of the disease. Immune cells, fibroblasts, specialized mesenchymal cells and microvasculature together make up the tumour microenvironment and have functional interactions with tumour cells. Classical Hodgkin's lymphoma (cHL) is characterized by only a few malignant cells and an abundance of inflammatory cells. Hodgkin and Reed-Sternberg (HRS) cells are surrounded by T and B cells admixed with plasma cells, macrophages, eosinophils and mast cells. A constitutive activity of NF-kappaB and an altered JAK-STAT signalling pathway are part of the biological background associated with the increased expression of cytokines and cytokine receptors seen in HRS cells. Over-expression of the members of the TNF receptor family, especially CD30 and CD40, is a hallmark of HRS cells. cHL is a tumour where aberrant cytokine production contributes not only to the proliferation of HRS cells but also to the maintenance of an appropriate environment for the tumour cells. In addition, several chemokines contribute to the composition of the inflammatory background in cHL. This review summarizes updated information on the complex interactions between the HRS cells and their tissue microenvironment and highlights the development of newer therapeutic strategies aimed at targeting the non-malignant inflammatory/immune cellular components of HL that are involved in cancer cell growth and/or immune escape. (c) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20527019     DOI: 10.1002/path.2711

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  90 in total

1.  Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma.

Authors:  Marta Celegato; Cinzia Borghese; Naike Casagrande; Maurizio Mongiat; Xaver U Kahle; Alice Paulitti; Michele Spina; Alfonso Colombatti; Donatella Aldinucci
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

2.  Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Authors:  Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

Review 3.  Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions.

Authors:  Julia Kravchenko; Emanuela Corsini; Marc A Williams; William Decker; Masoud H Manjili; Takemi Otsuki; Neetu Singh; Faha Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson; Leroy Lowe; H Kim Lyerly
Journal:  Carcinogenesis       Date:  2015-05-22       Impact factor: 4.944

4.  The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells.

Authors:  K Ullrich; F Blumenthal-Barby; B Lamprecht; K Köchert; D Lenze; M Hummel; S Mathas; B Dörken; M Janz
Journal:  Leukemia       Date:  2014-12-09       Impact factor: 11.528

Review 5.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

Review 6.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

7.  Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.

Authors:  Luigi Aloj; Laura D'Ambrosio; Michela Aurilio; Anna Morisco; Ferdinando Frigeri; Corradina Caraco'; Francesca Di Gennaro; Gaetana Capobianco; Leonardo Giovannoni; Hans D Menssen; Dario Neri; Antonio Pinto; Secondo Lastoria
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

8.  Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.

Authors:  Adam Gibb; Craig Jones; Adrian Bloor; Samar Kulkarni; Tim Illidge; Kim Linton; John Radford
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

9.  Hemophagocytic Syndrome Associated with Hodgkin's Lymphoma First Presenting as Fever and Pancytopenia.

Authors:  Ramon Andrade Bezerra de Mello; Elsa Fonseca; Manuela Brochado; João Manuel Quinaz
Journal:  Case Rep Med       Date:  2010-11-07

10.  Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment.

Authors:  S Montes-Moreno
Journal:  Adv Hematol       Date:  2010-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.